Efficacy and safety of antifungals in pediatric patients

Early Human Development

Volumn 87, Issue SUPPL., 2011, Pages

  Groll, Andreas H ^a  

^a UNIVERSITY HOSPITAL MÜNSTER   (Germany)

Author keywords

Amphotericin B; Antifungal agents; Aspergillosis; Azoles; Candidiasis; Echinocandins; Efficacy; Mycoses; Prevention; Recommendations; Safety; Treatment

Indexed keywords

AMPHOTERICIN B CHOLESTEROL SULFATE; AMPHOTERICIN B LIPID COMPLEX; ANIDULAFUNGIN; ANTIFUNGAL AGENT; CASPOFUNGIN; FLUCONAZOLE; MICAFUNGIN; VORICONAZOLE;

ARTICLE; ASPERGILLOSIS; ASPERGILLUS; CANDIDA; CANDIDIASIS; CRYPTOCOCCAL MENINGITIS; DOSE RESPONSE; DRUG DOSE ESCALATION; DRUG DOSE SEQUENCE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FUSARIOSIS; GASTROINTESTINAL SYMPTOM; HUMAN; INJECTION SITE REACTION; INVASIVE ASPERGILLOSIS; INVASIVE CANDIDIASIS; LIVER TOXICITY; MYCOSIS; NEPHROTOXICITY; NONHUMAN; PHOTOSENSITIVITY; PHOTOTOXICITY; PSEUDALLESCHERIASIS; RASH; RECOMMENDED DRUG DOSE; SIDE EFFECT; SKIN DISEASE;

ANTIFUNGAL AGENTS; CHILD; DRUG DESIGN; HUMANS; IMMUNOCOMPROMISED HOST; MODELS, BIOLOGICAL; PEDIATRICS; PREVENTIVE MEDICINE; TREATMENT OUTCOME;

EID: 79951812815     PISSN: 03783782     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.earlhumdev.2011.01.016     Document Type: Article

References (42)

1. Dornbusch H.J., Manzoni P., Roilides E., Walsh T.J., Groll A.H. Invasive fungal infections in children. Pediatr Infect Dis J 2009, 28:734-737.
2. European Community Regulation (EC) No 1901/2006 of the European Parliament and of the Council of medicinal products for paediatric use, amended by Regulation (EC) No 1902/2006 2006, Accessed July 26, 2010. http://serviziweb.unimol.it/unimol/allegati/pagine/5762/ceci.pdf.
3. European Medicines Agency ICH Topic E 11 Clinical Investigation of Medicinal Products in the Paediatric Population. Note for guidance on clinical investigation of medicinal products in the paediatric population (CPMP/ICH/2711/99) 2001, Accessed July 26, 2010. http://www.tga.gov.au/docs/pdf/euguide/ich/271199en.pdf.
4. Walsh T.J., Adamson P.C., Seibel N.L., Flynn P.M., Neely M.N., Schwartz C., et al. Pharmacokinetics, safety, and tolerability of caspofungin in children and adolescents. Antimicrob Agents Chemother 2005, 49:4536-4545.
5. Zaoutis T.E., Jafri H.S., Huang L.M., Locatelli F., Barzilai A., Ebell W., et al. A prospective, multicenter study of caspofungin for the treatment of documented Candida or Aspergillus infections in pediatric patients. Pediatrics 2009, 123:877-884.
6. Maertens J.A., Madero L., Reilly A.F., Lehrnbecher T., Groll A.H., Jafri H.S., et al. A randomized, double-blind, multicenter study of caspofungin versus liposomal amphotericin B for empiric antifungal therapy in pediatric patients with persistent fever and neutropenia. Pediatr Infect Dis J 2010, 29:415-420.
7. Seibel N.L., Schwartz C., Arrieta A., Flynn P., Shad A., Albano E., et al. Safety, tolerability, and pharmacokinetics of Micafungin (FK463) in febrile neutropenic pediatric patients. Antimicrob Agents Chemother 2005, 49:3317-3324.
8. van Burik J.A., Ratanatharathorn V., Stepan D.E., Miller C.B., Lipton J.H., Vesole D.H., et al. Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation. Clin Infect Dis 2004, 39:1407-1416.
9. Queiroz-Telles F., Berezin E., Leverger G., Freire A., van der Vyver A., Chotpitayasunondh T., et al. Micafungin versus liposomal amphotericin B for pediatric patients with invasive candidiasis: substudy of a randomized double-blind trial. Pediatr Infect Dis J 2008, 27:820-826.
10. Walsh T.J., Teppler H., Donowitz G.R., Maertens J.A., Baden L.R., Dmoszynska A., et al. Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. N Engl J Med 2004, 351:1391-1402.
11. Kuse E.R., Chetchotisakd P., da Cunha C.A., Ruhnke M., Barrios C., Raghunadharao D., et al. Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial. Lancet 2007, 369:1519-1527.
12. Hope W.W., Seibel N.L., Schwartz C.L., Arrieta A., Flynn P., Shad A., et al. Population pharmacokinetics of micafungin in pediatric patients and implications for antifungal dosing. Antimicrob Agents Chemother 2007, 51:3714-3719.
13. Walsh T.J., Karlsson M.O., Driscoll T., Arguedas A.G., Adamson P., Saez-Llorens X., et al. Pharmacokinetics and safety of intravenous voriconazole in children after single- or multiple-dose administration. Antimicrob Agents Chemother 2004, 48:2166-2172.
14. Karlsson M.O., Lutsar I., Milligan P.A. Population pharmacokinetic analysis of voriconazole plasma concentration data from pediatric studies. Antimicrob Agents Chemother 2009, 53:935-944.
15. Neely M., Rushing T., Kovacs A., Jelliffe R., Hoffman J. Voriconazole pharmacokinetics and pharmacodynamics in children. Clin Infect Dis 2010, 50:27-36.
16. Groll A.H., Tragiannidis A. Update on antifungal agents for paediatric patients. Clin Microbiol Infect 2010, 16:1343-1353.
17. Cornely O.A., Maertens J., Bresnik M., Ebrahimi R., Ullmann A.J., Bouza E., et al. Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial). Clin Infect Dis 2007, 44:1289-1297.
18. Novelli V., Holzel H. Safety and tolerability of fluconazole in children. Antimicrob Agents Chemother 1999, 43:1955-1960.
19. Groll A.H., Piscitelli S.C., Walsh T.J. Clinical pharmacology of systemic antifungal agents: a comprehensive review of agents in clinical use, current investigational compounds, and putative targets for antifungal drug development. Adv Pharmacol 1998, 44:343-500.
20. Pappas P.G., Kauffman C.A., Andes D., Benjamin D.K., Calandra T.F., Edwards J.E., et al. Guidelines for treatment of candidiasis. Clin Infect Dis 2009, 48:503-535.
21. Wade K.C., Wu D., Kaufman D.A., Ward R.M., Benjamin D.K., Sullivan J.E., et al. Population pharmacokinetics of fluconazole in young infants. Antimicrob Agents Chemother 2008, 52:4043-4049.
22. Wade K.C., Benjamin D.K., Kaufman D.A., Ward R.M., Smith P.B., Jayaraman B., et al. Fluconazole dosing for the prevention or treatment of invasive candidiasis in young infants. Pediatr Infect Dis J 2009, 28:717-723.
23. Kaufman D., Boyle R., Hazen K.C., Patrie J.T., Robinson M., Donowitz L.G. Fluconazole prophylaxis against fungal colonization and infection in preterm infants. N Engl J Med 2001, 345:1660-1666.
24. Manzoni P., Stolfi I., Pugni L., Decembrino L., Magnani C., Vetrano G., et al. A multicenter, randomized trial of prophylactic fluconazole in preterm neonates. N Engl J Med 2007, 356:2483-2495.
25. Walsh T.J., Lutsar I., Driscoll T., Dupont B., Roden M., Ghahramani P., et al. Voriconazole in the treatment of aspergillosis, scedosporiosis and other invasive fungal infections in children. Pediatr Infect Dis J 2002, 21:240-248.
26. Cowen E.W., Nguyen J.C., Miller D.D., McShane D., Arron S.T., Prose N.S., et al. Chronic phototoxicity and aggressive squamous cell carcinoma of the skin in children and adults during treatment with voriconazole. J Am Acad Dermatol 2010, 62:31-37.
27. Neely M., Jafri H.S., Seibel N., Knapp K., Adamson P.C., Bradshaw S.K., et al. Pharmacokinetics and safety of caspofungin in older infants and toddlers. Antimicrob Agents Chemother 2009, 53:1450-1456.
28. Sáez-Llorens X., Macias M., Maiya P., Pineros J., Jafri H.S., Chatterjee A., et al. Pharmacokinetics and safety of caspofungin in neonates and infants less than 3months of age. Antimicrob Agents Chemother 2009, 53:869-875.
29. Zaoutis T., Lehrnbecher T., Groll A.H., Steinbach W.J., Jafri H.S., Maertens J., et al. Safety experience with caspofungin in pediatric patients. Pediatr Infect Dis J 2009, 28:1132-1135.
30. Natarajan G., Lulic-Botica M., Rongkavilit C., Pappas A., Bedard M. Experience with caspofungin in the treatment of persistent fungemia in neonates. J Perinatol 2005, 25:770-777.
31. Odio C.M., Araya R., Pinto L.E., Castro C.E., Vasquez S., Alfaro B., et al. Caspofungin therapy of neonates with invasive candidiasis. Pediatr Infect Dis J 2004, 23:1093-1097.
32. Groll A.H., Tragiannidis A. Recent advances in antifungal prevention and treatment. Semin Hematol 2009, 46:212-229.
33. Wiley J.M., Seibel N.L., Walsh T.J. Efficacy and safety of amphotericin B lipid complex in 548 children and adolescents with invasive fungal infections. Pediatr Infect Dis J 2005, 24:167-174.
34. Walsh T.J., Anaissie E.J., Denning D.W., Herbrecht R., Kontoyiannis D.P., Marr K.A., et al. Infectious Diseases Society of America. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis 2008, 46:327-360.
35. Herbrecht R., Denning D.W., Patterson T.F., Bennett J.E., Greene R.E., Oestmann J.W., et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002, 347:408-415.
36. Maertens J., Raad I., Petrikkos G., Boogaerts M., Selleslag D., Petersen F.B., et al. Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy. Clin Infect Dis 2004, 39:1563-1571.
37. Wirk B., Wingard J.R. Combination antifungal therapy: from bench to bedside. Curr Fungal Infect Rep 2008, 2:43-48.
38. Walsh T.J., Groll A., Hiemenz J., Fleming R., Roilides E., Anaissie E. Infections due to emerging and uncommon medically important fungal pathogens. Clin Microbiol Infect 2004, 10(Suppl 1):48-66.
39. Perfect J.R., Marr K.A., Walsh T.J., Greenberg R.N., DuPont B., de la Torre-Cisneros J., et al. Voriconazole treatment for less-common, emerging, or refractory fungal infections. Clin Infect Dis 2003, 36:1122-1131.
40. Raad I., Chapman S., Bradsher R., Morrison V., Goldman M., Graybill J. Posaconazole salvage therapy for invasive fungal infections. Abstracts of the 44th Interscience Conference on Antimicrobial Agents and Chemotherapy 2004, American Society for Microbiology, Washington DC, Abstr. M-669; Washington, DC.
41. van Burik J.A., Hare R.S., Solomon H.F., Corrado M.L., Kontoyiannis D.P. Posaconazole is effective as salvage therapy in zygomycosis: a retrospective summary of 91 cases. Clin Infect Dis 2006, 42:e61-e65.
42. Prentice H.G., Hann I.M., Herbrecht R., Aoun M., Kvaloy S., Catovsky D., et al. A randomized comparison of liposomal versus conventional amphotericin B for the treatment of pyrexia of unknown origin in neutropenic patients. Br J Haematol 1997, 98:711-718.